Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
3 Things About Novo Nordisk That Smart Investors Know
08:00am, Monday, 10'th Apr 2023
Novo Nordisk is selling semaglutide at an impressive scale. But dividend investors might not be pleased with its history of payouts.
Could Novo Nordisk Stock Help You Become a Millionaire?
07:59am, Saturday, 08'th Apr 2023
Novo Nordisk's sales have risen by more than 40% in the past five years. Even more growth opportunities are ahead for the company as its business focuses on two high-need areas: diabetes and obesity c
3 No-Brainer Stocks to Buy in a New Bull Market
06:11am, Saturday, 08'th Apr 2023
Novo Nordisk has exceptional growth prospects with its diabetes and obesity drugs. Pfizer isn't getting the respect it deserves.
5 Diverse Medical Stocks to Buy for 2023 and Beyond
07:01pm, Thursday, 06'th Apr 2023
The top and bottom-line growth make these Zacks Medical stocks very attractive.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Thursday, 06'th Apr 2023
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
09:15am, Thursday, 06'th Apr 2023
Novo Nordisk controls almost one-third of the entire worldwide diabetes market. Patent protection on Ozempic and Rybelsus, which treat type 2 diabetes and can help with weight loss, lasts until 2032 i
4 Low-Beta Stocks to Buy to Endure Market Volatility
08:24am, Tuesday, 04'th Apr 2023
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.
3 Stocks That Could Benefit From the Ozempic Craze
09:45am, Thursday, 30'th Mar 2023
Novo Nordisk's business has been red-hot, thanks to soaring obesity-related revenue. Eli Lilly has its own promising weight-loss treatment which could be a game changer.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
Drugs for obesity are a massive market, says Mizuho's Jared Holz
06:59pm, Wednesday, 29'th Mar 2023
Jared Holz, Mizuho, joins 'Fast Money' to discuss obesity drugs with CNBC's Tyler Mathisen and the Fast Money traders.
People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication
01:05pm, Wednesday, 29'th Mar 2023
Some people may actually gain back more weight than they initially lost after stopping obesity drugs Ozempic and Wegovy.
Novo Nordisk (NVO) is a Great Momentum Stock: Should You Buy?
01:44pm, Tuesday, 28'th Mar 2023
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal
01:45pm, Monday, 27'th Mar 2023
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win
02:37pm, Friday, 24'th Mar 2023
Novo Nordisk stock popped Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients. The post The Ozempic Obesity Battle Is Heating Up With Novo Scori
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
10:40am, Thursday, 23'rd Mar 2023
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of t
